The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 14, 2017
Filed:
Apr. 14, 2015
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Istituto Di Ricerche Di Biologia P. Angeletti S.r.l., Rome, IT;
Indiana University Research and Technology Corporation, Indianapolis, IN (US);
Paul E. Carrington, Rahway, NJ (US);
George J. Eiermann, Rahway, NJ (US);
Donald J. Marsh, Rahway, NJ (US);
Joseph M. Metzger, Rahway, NJ (US);
Alessandro Pocai, Rahway, NJ (US);
Ranabir Sinha Roy, Rahway, NJ (US);
Elisabetta Bianchi, Pommezia, IT;
Paolo Ingallinella, Pommezia, IT;
Antonello Pessi, Pommezia, IT;
Alessia Santoprete, Pommezia, IT;
Elena Capito, Pommezia, IT;
Richard Dimarchi, Indianapolis, IN (US);
Brian Ward, Bloomington, IN (US);
MERCK SHARP & DOHME CORP., Rahway, NJ (US);
MSD ITALIA S.R.L., Rome, IT;
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Indianapolis, IN (US);
Abstract
Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.